MOTS-c and Retatrutide Together: What Is Known
MOTS-c and Retatrutide taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Side by side
Showing 11 of 13 fields where the two differ. Category, Evidence strength are the same or both unknown.
| Field | MOTS-c | Retatrutide |
|---|---|---|
| Class | Mitochondrial-derived peptide | GLP-1 / GIP / glucagon triple agonist |
| Also called | mots | reta, GLP-3, LY3437943 |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | PCAC voted 7–5 for 503A (Jul 2026) | Investigational · phase 3 |
| PCAC vote, Jul 2026 | PCAC voted 7–5 for the 503A list (Jul 2026); not finalized | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times. | Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654 | Human RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954 |
| Human studies we summarised | 7 human (4 randomized or controlled) of 15 summarised | 11 human (11 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 5 mg, 10 mg, 20 mg, 40 mg | 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
MOTS-c vs Retatrutide
Choosing between the two rather than combining them? The comparison lines them up field by field.
Retatrutide: late-phase human trials
TRIUMPH-1 randomised 2339 adults with obesity to retatrutide or placebo and reported weight loss at each of its doses against 3.9% on placebo.[1]
Within TRIUMPH-1, a subgroup with obstructive sleep apnoea showed larger falls in apnoea events per hour than placebo.[1]
MOTS-c: mouse and cell work, not injected-peptide trials in people
The MOTS-c evidence behind this pairing is from mice, where treatment prevented insulin resistance linked to ageing and a high-fat diet.[22]
Its human data measure the body's own circulating MOTS-c, not an injected product: a 16-week exercise trial in breast cancer survivors found levels rose after exercise in one subgroup.[10]
In ageing mice, intermittent MOTS-c treatment started late in life increased physical capacity. This is an animal result.[23]
No study of the pair
A PubMed title and abstract search on 2 Oct 2026 for MOTS-c together with retatrutide returned 0 records.
Calculated from pubmed query ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab]); records matched 0; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
Drugs@FDA has no entry for MOTS-c.[24]
Sport and legal status
WADA lists MOTS-c by name among AMPK activators, banned at all times.[6]
FDA says retatrutide cannot be used in compounding under federal law.[25]
Common questions
Can MOTS-c be taken with retatrutide?
No study has tested it. MOTS-c's human literature measures endogenous levels, and FDA lists retatrutide as unapproved and barred from compounding.[25]
Does MOTS-c help with weight loss in people?
Only mouse data show weight effects; in mice, treatment prevented diet-induced obesity.[22]
Sources
- 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 4FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 6World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 7Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
- 8Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
- 9Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
- 10Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 17Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 18Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
- 19PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (retatrutide[tiab] OR LY3437943[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 21PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 22The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.Cell metabolism · 2015PMID 25738459Accessed 2 Oct 2026
- 23MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.Nature communications · 2021PMID 33473109Accessed 2 Oct 2026
- 24Drugs@FDA (openFDA) search: active ingredient "MOTS-c"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 25Official web pageOfficial web page · web page
Found an error? Report a correction.